The stock of Acceleron Pharma Inc (NASDAQ:XLRN) is a huge mover today! About 225,053 shares traded hands. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 11.89% since April 28, 2016 and is uptrending. It has outperformed by 5.96% the S&P500.
The move comes after 5 months positive chart setup for the $1.22 billion company. It was reported on Dec, 1 by Barchart.com. We have $37.90 PT which if reached, will make NASDAQ:XLRN worth $97.60M more.
Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on February, 23. They expect $-0.60 EPS, up 25.93% or $0.21 from last year’s $-0.81 per share. After $-0.55 actual EPS reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.
Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage
Out of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Acceleron Pharma has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by FBR Capital on Monday, January 18. Morgan Stanley initiated the shares of XLRN in a report on Thursday, August 13 with “Overweight” rating. As per Wednesday, April 27, the company rating was initiated by Barclays Capital. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. The rating was initiated by Janney Capital on Thursday, December 17 with “Neutral”. The firm has “Outperform” rating given on Friday, January 15 by FBR Capital. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Overweight” rating by Barclays Capital on Monday, June 13. The stock has “Outperform” rating given by Oppenheimer on Monday, February 1. On Thursday, September 29 the stock rating was initiated by Citigroup with “Neutral”. The firm has “Outperform” rating by Oppenheimer given on Friday, November 20.
According to Zacks Investment Research, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.49, from 1.49 in 2016Q1. The ratio dropped, as 15 funds sold all Acceleron Pharma Inc shares owned while 32 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 28.02 million shares or 2.80% less from 28.83 million shares in 2016Q1.
Parametric Associates Limited Liability Company holds 8,797 shares or 0% of its portfolio. Sectoral Asset has 1.83% invested in the company for 522,294 shares. California Pub Employees Retirement last reported 0% of its portfolio in the stock. Wells Fargo & Co Mn has 23,483 shares for 0% of their US portfolio. Foresite Capital Management Ii Llc has invested 1.13% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). American Century Companies last reported 0% of its portfolio in the stock. Voya Invest Management Limited Liability Co last reported 0% of its portfolio in the stock. Gotham Asset Management has invested 0.01% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). The Illinois-based Oak Ridge Limited Liability Corporation has invested 1.17% in Acceleron Pharma Inc (NASDAQ:XLRN). Moreover, Fmr Lc has 0.03% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 5.57 million shares. D E Shaw And accumulated 0% or 35,205 shares. Ladenburg Thalmann holds 0% or 13 shares in its portfolio. Artal Grp Sa accumulated 100,000 shares or 0.07% of the stock. Nationwide Fund Advsrs has 0% invested in the company for 25,951 shares.
Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 9 selling transactions for $58.34 million net activity. The insider Knopf John L sold 100,000 shares worth $3.39 million. Another trade for 21,438 shares valued at $689,017 was made by Quisel John D on Monday, September 12. On Wednesday, November 16 the insider George Jean sold $17.41M. Another trade for 32,270 shares valued at $1.12 million was made by Ertel Steven D on Friday, July 1. MCLAUGHLIN KEVIN F sold 25,300 shares worth $876,898. Sherman Matthew L sold 26,000 shares worth $903,143. $1.78M worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares were sold by Kumar Ravindra.
More recent Acceleron Pharma Inc (NASDAQ:XLRN) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on September 19, 2013. Also Marketwatch.com published the news titled: “Acceleron Pharma tabs Bayer exec as next CEO” on September 27, 2016. Businesswire.com‘s news article titled: “Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented …” with publication date: November 30, 2016 was also an interesting one.
XLRN Company Profile
Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. The Firm focuses on discovering and developing therapeutic candidates that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.